NCT05857878已完成1 期
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1815368 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related by the investigator
研究概览
简要总结
This trial aims to investigate safety, tolerability, and pharmacokinetics following multiple rising doses of BI 1815368 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests.
- •Age of 18 to 55 years (inclusive).
- •Body mass index (BMI) of 19 to 29.9 kg/m2 (inclusive).
- •Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator.
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm).
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair).
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders.
- •History of relevant orthostatic hypotension, fainting spells, or blackouts. Further exclusion criteria apply.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Matching placebo (Drug)
Dose Group 1
Experimental
干预措施: BI 1815368 (Drug)
Dose Group 2
Experimental
干预措施: BI 1815368 (Drug)
Dose Group 3
Experimental
干预措施: BI 1815368 (Drug)
Dose Group 4
Experimental
干预措施: BI 1815368 (Drug)
Dose Group 5
Experimental
干预措施: BI 1815368 (Drug)
Dose Group 6
Experimental
干预措施: BI 1815368 (Drug)
结局指标
主要结局
Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related by the investigator
时间窗: Up to 29 days
次要结局
- Minimum concentration of BI 1815368 in plasma at steady state over a uniform dosing interval τ (Cmin,ss)(Up to 16 days)
- Maximum measured concentration of BI 1815368 in plasma at steady state over a uniform dosing interval τ (Cmax,ss)(Up to 16 days)
- Area under the concentration-time curve of BI 1815368 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)(Up to 16 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Staccato Loxapine Multidose PKVolunteers on Chronic, Stable Antipsychotic RegimensNCT00555412Alexza Pharmaceuticals, Inc.40
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)HealthyNCT02337283Boehringer Ingelheim96
已完成
1 期
Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic PatientsHealthyAsthmaNCT01651598Boehringer Ingelheim57
已完成
1 期
Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741HealthyNCT01068028Orion Corporation, Orion Pharma49
已完成
1 期
Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741HealthyNCT00792493Orion Corporation, Orion Pharma51